Literature DB >> 11600356

Clearance of infection with Mycobacterium bovis BCG in mice is enhanced by treatment with S28463 (R-848), and its efficiency depends on expression of wild-type Nramp1 (resistance allele).

J Moisan1, W Wojciechowski, C Guilbault, C Lachance, S Di Marco, E Skamene, G Matlashewski, D Radzioch.   

Abstract

The mouse bcg host resistance gene is known to control the activation of host macrophages for killing of intracellular parasites like Leishmania donovani as well as intracellular bacteria, including Mycobacterium bovis BCG and Salmonella enterica serovar Typhimurium. The Nramp1 gene has been mapped to this locus and affects the efficiency of macrophage activation. It has been shown that imidazoquinoline compounds, including S28463, are able to improve the clearance of a number of intracellular pathogens such as herpes simplex virus 2, human papillomavirus, and Leishmania. The goal of this study was to determine whether S28463 is efficient against infection with another intracellular pathogen, M. bovis BCG, and to determine the molecular basis underlying this effect. To achieve this, B10A.Nramp1(r) and B10A.Nramp1(-/-) mice were infected with M. bovis BCG and treated with S28463. The bacterial content in the spleen from these mice was assayed by a colony-forming assay. In addition, in vitro experiments were performed using bone marrow-derived macrophage cell lines from these mice. These cells were treated with S28463 and/or gamma interferon (IFN-gamma), and nitric oxide (NO) production was measured. Our study was able to show that S28463 acts in synergy with IFN-gamma to increase the production of NO in vitro. We were also able to demonstrate that mice that carried the resistant allele of the Nramp1 gene and were infected with M. bovis BCG responded to treatment with S28463, resulting in a decreased bacterial load after 2 weeks of treatment. Mice that do not express the Nramp1 gene responded only to a very large dose of S28463, and the response was not as efficient as that observed in mice carrying a wild-type Nramp1 allele. Our data provide evidence for the potential of S28463 as an immunomodulator that may be helpful in designing efficient strategies to improve host defense against mycobacterial infection.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11600356      PMCID: PMC90782          DOI: 10.1128/AAC.45.11.3059-3064.2001

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  52 in total

1.  Dendritic cell maturation and subsequent enhanced T-cell stimulation induced with the novel synthetic immune response modifier R-848.

Authors:  C L Ahonen; S J Gibson; R M Smith; L K Pederson; J M Lindh; M A Tomai; J P Vasilakos
Journal:  Cell Immunol       Date:  1999-10-10       Impact factor: 4.868

Review 2.  The natural resistance-associated macrophage protein and susceptibility to intracellular pathogens.

Authors:  R Bellamy
Journal:  Microbes Infect       Date:  1999-01       Impact factor: 2.700

3.  Imiquimod, a topical immune response modifier, induces migration of Langerhans cells.

Authors:  H Suzuki; B Wang; G M Shivji; P Toto; P Amerio; M A Tomai; R L Miller; D N Sauder
Journal:  J Invest Dermatol       Date:  2000-01       Impact factor: 8.551

4.  Correlation between pretreatment levels of interferon response genes and clinical responses to an immune response modifier (Imiquimod) in genital warts.

Authors:  I Arany; S K Tyring; M M Brysk; M A Stanley; M A Tomai; R L Miller; M H Smith; D J McDermott; H B Slade
Journal:  Antimicrob Agents Chemother       Date:  2000-07       Impact factor: 5.191

5.  Modification of immunological responses and clinical disease during topical R-837 treatment of genital HSV-2 infection.

Authors:  C J Harrison; L Jenski; T Voychehovski; D I Bernstein
Journal:  Antiviral Res       Date:  1988-12-01       Impact factor: 5.970

6.  Treatment of primary herpes simplex virus infection in guinea pigs by imiquimod.

Authors:  R L Miller; L M Imbertson; M J Reiter; J F Gerster
Journal:  Antiviral Res       Date:  1999-11       Impact factor: 5.970

7.  Effects of the immunomodulating agent R837 on acute and latent herpes simplex virus type 2 infections.

Authors:  D I Bernstein; C J Harrison
Journal:  Antimicrob Agents Chemother       Date:  1989-09       Impact factor: 5.191

8.  The use of imiquimod 5% cream for the treatment of superficial basal cell carcinomas in a basal cell nevus syndrome patient.

Authors:  M K Kagy; R Amonette
Journal:  Dermatol Surg       Date:  2000-06       Impact factor: 3.398

9.  The immune response modifiers imiquimod and R-848 are potent activators of B lymphocytes.

Authors:  M A Tomai; L M Imbertson; T L Stanczak; L T Tygrett; T J Waldschmidt
Journal:  Cell Immunol       Date:  2000-07-10       Impact factor: 4.868

10.  The imidazoquinolines, imiquimod and R-848, induce functional, but not phenotypic, maturation of human epidermal Langerhans' cells.

Authors:  R P Burns; B Ferbel; M Tomai; R Miller; A A Gaspari
Journal:  Clin Immunol       Date:  2000-01       Impact factor: 3.969

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.